Literature DB >> 29055517

Enhanced CD8+ cytolytic T cell responses in the peripheral circulation of patients with sarcoidosis and non-Löfgren's disease.

Venkata Ramanarao Parasa1, Helena Forsslund2, Tobias Enger2, Daniel Lorenz2, Susanna Kullberg2, Anders Eklund2, Magnus Sköld2, Jan Wahlström2, Johan Grunewald2, Susanna Brighenti3.   

Abstract

BACKGROUND: The role of CD4+ T cells in the immunopathogenesis of pulmonary sarcoidosis is well-established, while less is known about the phenotype and function of CD8+ cytolytic T cells (CTLs).
METHODS: CD8+ CTLs were explored in peripheral blood and bronchoalveolar lavage (BAL) samples obtained from up to 25 patients with sarcoidosis and 25 healthy controls. The proportion of CTLs was assessed by the expression of cytolytic effector molecules perforin, granzyme B and granulysin in CD8+ T cells, using flow cytometry. Cytolytic function in blood lymphocytes was assessed using a standard 51Cr-release assay. Patients with Löfgren´s syndrome (LS) and an acute disease onset, were compared to non-LS patients with an insidious onset.
RESULTS: Higher proportions of peripheral CD8+ CTLs expressing perforin and granzyme B were observed in sarcoidosis compared to healthy controls. Blood CTLs from non-LS patients had significantly higher expression of perforin, granzyme B and granulysin compared to matched BAL, while LS patients maintained lower levels of effector molecules in both compartments. Mitogen-stimulated peripheral lymphocytes from sarcoidosis patients, particularly from the non-LS group, showed a higher target cell lysis compared to controls.
CONCLUSION: These results demonstrated enhanced peripheral CD8+ CTL responses in sarcoidosis, especially in non-LS patients who have an increased risk of chronic disease. Further comprehensive clinical studies are warranted to increase our understanding of CD8+ CTL responses in sarcoidosis.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD8(+) cytolytic T cells; Granulysin; Granzyme B; Perforin; Sarcoidosis

Mesh:

Substances:

Year:  2017        PMID: 29055517     DOI: 10.1016/j.rmed.2017.10.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Immune Thrombocytopenic Purpura Secondary to Sarcoidosis.

Authors:  Aisha Barlas; Lintu Ramachandran
Journal:  Maedica (Bucur)       Date:  2022-03

2.  The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells.

Authors:  Michael A Paley; Brandi J Baker; S Richard Dunham; Nicole Linskey; Claudia Cantoni; Kenneth Lee; Lynn M Hassman; Jennifer Laurent; Elisha D O Roberson; David B Clifford; Wayne M Yokoyama
Journal:  J Neuroimmunol       Date:  2022-04-01       Impact factor: 3.221

3.  Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis.

Authors:  S Kullberg; N V Rivera; M Abo Al Hayja; J Grunewald; A Eklund
Journal:  Clin Exp Immunol       Date:  2020-04-22       Impact factor: 4.330

Review 4.  Key Players and Biomarkers of the Adaptive Immune System in the Pathogenesis of Sarcoidosis.

Authors:  Emily-Rose Zhou; Sergio Arce
Journal:  Int J Mol Sci       Date:  2020-10-07       Impact factor: 5.923

5.  Anti-inflammatory Properties of the Alpha-Melanocyte-Stimulating Hormone in Models of Granulomatous Inflammation.

Authors:  Abdolrazagh Hashemi Shahraki; Runxia Tian; Chongxu Zhang; Nevis L Fregien; Pablo Bejarano; Mehdi Mirsaeidi
Journal:  Lung       Date:  2022-06-18       Impact factor: 3.777

6.  T Lymphocyte Maturation Profile in the EBUS-TBNA Lymph Node Depending on the DLCO Parameter in Patients with Pulmonary Sarcoidosis.

Authors:  Elżbieta Rutkowska; Iwona Kwiecień; Joanna Bednarek; Rafał Sokołowski; Agata Raniszewska; Karina Jahnz-Różyk; Piotr Rzepecki
Journal:  Cells       Date:  2021-12-02       Impact factor: 6.600

7.  Adaptive immune system in pulmonary sarcoidosis-Comparison of peripheral and alveolar biomarkers.

Authors:  Miriana d'Alessandro; Laura Bergantini; Paolo Cameli; Fabrizio Mezzasalma; Rosa Metella Refini; Maria Pieroni; Piersante Sestini; Elena Bargagli
Journal:  Clin Exp Immunol       Date:  2021-07-07       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.